본문 바로가기

Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: a prospective, multicenter, observational study (RESOLVE-PRO)

문서 유형
연구출판물 · 학술지 논문
등재
ESCIKCIScopus
저널 순위
KCI Q4
저널
CLINICAL HYPERTENSION27(4) · pp.33 · 2021
피인용
Scopus 10KCI 0
FWCI (Scopus)
0.76
ISSN
2635-6325

저자

  1. 손일석제1저자경희대학교
  2. 임상현가톨릭대학교
  3. 김지희Department of Internal Medicine, Division of Cardiology, St. Vincent’s Hospital
  4. 박상민Department of Cardiology, Nowon Eulji Medical Center
  5. 홍범기연세대학교
  6. 이창훈중앙보훈병원 내과
  7. 이상현양산부산대학교병원 순환기내과
  8. 장대일경희대학교
  9. 주성필전남대학교
  10. 이상찬Department of Neurology, Dong-Eui Hospital
  11. 이용호연세대학교
  12. Jeon Dong WoonNational Health Insurance Service Ilsan Hospital
  13. 정경태Department of Cardiology, Nowon Eulji Medical Center
  14. Si Jae RheeMedical Affairs Department, Daiichi Sankyo Korea Co., Ltd.
  15. 조윤진Medical Affairs Department, Daiichi Sankyo Korea Co., Ltd.
  16. 김종진교신저자Department of Cardiology, CHA Gangnam Medical Center

초록

In this prospective, multicenter, non-comparative observational study, the effectiveness and safety of the triple single-pill combination (SPC) of olmesartan/amlodipine/hydrochlorothiazide (OM/AML/HCTZ) were evaluated in a real clinical practice setting in Korean patients with essential hypertension.A total of 3752 patients were enrolled and followed for 12 months after administration of OM/AML/HCTZ. Primary endpoint was change from baseline to month 6 in the mean systolic blood pressure (SBP). Secondary endpoints included changes from baseline in the mean SBP at month 3, 9, 12 and the mean diastolic blood pressure (DBP) at month 3, 6, 9, 12; changes in the mean SBP/DBP according to age and underlying risk factors; and blood pressure control rate (%) at different time points. Adherence to and satisfaction with OM/AML/HCTZ treatment among patients and physicians were assessed by medication possession ratio (MPR) and numeric rating scale, respectively, as exploratory endpoints. Safety was evaluated by the incidence and severity of adverse events (AEs) as well as the discontinuation rate due to AEs. OM/AML/HCTZ administration led to significant reductions in the mean SBP/DBP by 11.5/6.6, 12.3/7.0, 12.3/7.2, and 12.8/7.4 mmHg from baseline to month 3, 6, 9 and 12, respectively ( P < 0.0001). The BP reductions were maintained throughout the 1-year observation period in all patients with different age groups and risk factors (diabetes mellitus, cardiovascular disease, and renal disease). The BP control rate (%) of < 140/90 mmHg was 65.9, 67.9, 68.9, and 70.6% at month 3, 6, 9, and 12, respectively. The mean MPR during the observation period was 0.96. The safety results were consistent with the previously reported safety profile of OM/AML/HCTZ. Treatment with the triple SPC of OM/AML/HCTZ demonstrated significant effectiveness in reducing SBP/DBP and achieving target BP control with high adherence over the 1-year observation period in Korean hypertensive patients and was well-tolerated. CRIS, KCT0002196 , Registered 3 May 2016.

키워드

HypertensionObservational studyOlmesartanAmlodipineHydrochlorothiazideReal-worldSingle-pill combinationKorea

식별자

Scopus EID
2-s2.0-85127089084
KCI
ART002788629